Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M

Immunovant, Inc.

FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.
Phase 3 MG trial initiation on track by end of June 2022; top-line data expected H2 2024.
Cash $493.8M as of March 31, 2022 provides runway into calendar year 2025.
FY2022 net loss $156.7M ($1.43/share) vs FY2021 $107.4M ($1.22/share); R&D spend $101.8M.
Company expects to announce two new batoclimab indications by August 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.